AXYS Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AXYS Pharmaceuticals Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TomOrt who wrote (190)	11/28/1998 8:03:00 PM
From: Tiger	Read Replies (1) of 455

To thread, NEW YORK, Nov 27 (Reuters) - Morgan Stanley analyst Doug Lind told clients the market environment is favoring product-oriented mid-cap biotechnology stocks and longer-term stories are still out of favor. -- As a result, he updated his outlook for several biotechnology companies on Friday. -- raised his price target for Agouron Pharmaceuticals Inc. (AGPH - news) to $54 from $45. Shares off 1/2 to 42-5/8. -- cut his price target for Axys Pharmaceuticals Inc. (AXPH - news) to $10 from $13. Shares off 1/2 to 42-5/8. -- cut his price target on Nanogen Inc. (NGEN - news) to $11 from $16. Shares up 3/8 to 5-3/4. Tiger

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next